To include your compound in the COVID-19 Resource Center, submit it here.

CF102: Interim Phase I/II data

Interim data from an ongoing, open-label, dose-escalation, Israeli Phase I/II trial in 18 patients with

Read the full 152 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE